SkylineDx Awarded CE-IVD Registration for MMprofiler

SkylineDx has won CE-IVD registration for its MMprofiler, a prognostic test to determine the level of risk of a patient with multiple myeloma, for distribution in the EU.

The test helps to more accurately measure the prognosis of multiple myeloma patients using the SKY92 gene signature by classifying them into a “high” or “standard” risk group.

Patients with a “high” risk classification have a poor prognosis compared with those with a standard risk profile. — Michael Cipriano